<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE rdf:RDF [
	<!ENTITY cmns-av "https://www.omg.org/spec/Commons/AnnotationVocabulary/">
	<!ENTITY cmns-cds "https://www.omg.org/spec/Commons/CodesAndCodeSets/">
	<!ENTITY cmns-cls "https://www.omg.org/spec/Commons/Classifiers/">
	<!ENTITY cmns-cmp "https://www.omg.org/spec/Commons/Composites/">
	<!ENTITY cmns-col "https://www.omg.org/spec/Commons/Collections/">
	<!ENTITY cmns-cxtdsg "https://www.omg.org/spec/Commons/ContextualDesignators/">
	<!ENTITY cmns-doc "https://www.omg.org/spec/Commons/Documents/">
	<!ENTITY cmns-dsg "https://www.omg.org/spec/Commons/Designators/">
	<!ENTITY cmns-ge-euj "https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/">
	<!ENTITY cmns-id "https://www.omg.org/spec/Commons/Identifiers/">
	<!ENTITY cmns-org "https://www.omg.org/spec/Commons/Organizations/">
	<!ENTITY cmns-prd "https://www.omg.org/spec/Commons/ProductsAndServices/">
	<!ENTITY cmns-pts "https://www.omg.org/spec/Commons/PartiesAndSituations/">
	<!ENTITY cmns-qtu "https://www.omg.org/spec/Commons/QuantitiesAndUnits/">
	<!ENTITY cmns-ra "https://www.omg.org/spec/Commons/RegistrationAuthorities/">
	<!ENTITY cmns-rga "https://www.omg.org/spec/Commons/RegulatoryAgencies/">
	<!ENTITY cmns-txt "https://www.omg.org/spec/Commons/TextDatatype/">
	<!ENTITY dct "http://purl.org/dc/terms/">
	<!ENTITY idmp-chg "https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/">
	<!ENTITY idmp-ctcae "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/">
	<!ENTITY idmp-doco "https://spec.pistoiaalliance.org/idmp/ontology/EXT/DocumentComponents/">
	<!ENTITY idmp-dtp "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/">
	<!ENTITY idmp-eura "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/">
	<!ENTITY idmp-eurga "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/">
	<!ENTITY idmp-meddra "https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/">
	<!ENTITY idmp-mprd "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/">
	<!ENTITY idmp-nara "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/">
	<!ENTITY idmp-narga "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/">
	<!ENTITY idmp-phprd "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11616-PharmaceuticalProducts/">
	<!ENTITY idmp-plu "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/">
	<!ENTITY idmp-ra "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/">
	<!ENTITY idmp-snomed "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/">
	<!ENTITY idmp-sub "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/">
	<!ENTITY idmp-ucum "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/">
	<!ENTITY idmp-uom "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/">
	<!ENTITY lcc-3166-1 "https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/">
	<!ENTITY lcc-639-1 "https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/">
	<!ENTITY lcc-cr "https://www.omg.org/spec/LCC/Countries/CountryRepresentation/">
	<!ENTITY lcc-lr "https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/">
	<!ENTITY mvf-trm "https://www.omg.org/spec/MVF/ISO1087-VocabularyForTermsAndDefinitions/">
	<!ENTITY owl "http://www.w3.org/2002/07/owl#">
	<!ENTITY po "http://purl.org/spar/po/">
	<!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#">
	<!ENTITY skos "http://www.w3.org/2004/02/skos/core#">
	<!ENTITY snomed "https://lookup.snomedtools.org/">
	<!ENTITY xsd "http://www.w3.org/2001/XMLSchema#">
]>
<rdf:RDF xml:base="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/"
	xmlns:cmns-av="https://www.omg.org/spec/Commons/AnnotationVocabulary/"
	xmlns:cmns-cds="https://www.omg.org/spec/Commons/CodesAndCodeSets/"
	xmlns:cmns-cls="https://www.omg.org/spec/Commons/Classifiers/"
	xmlns:cmns-cmp="https://www.omg.org/spec/Commons/Composites/"
	xmlns:cmns-col="https://www.omg.org/spec/Commons/Collections/"
	xmlns:cmns-cxtdsg="https://www.omg.org/spec/Commons/ContextualDesignators/"
	xmlns:cmns-doc="https://www.omg.org/spec/Commons/Documents/"
	xmlns:cmns-dsg="https://www.omg.org/spec/Commons/Designators/"
	xmlns:cmns-ge-euj="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"
	xmlns:cmns-id="https://www.omg.org/spec/Commons/Identifiers/"
	xmlns:cmns-org="https://www.omg.org/spec/Commons/Organizations/"
	xmlns:cmns-prd="https://www.omg.org/spec/Commons/ProductsAndServices/"
	xmlns:cmns-pts="https://www.omg.org/spec/Commons/PartiesAndSituations/"
	xmlns:cmns-qtu="https://www.omg.org/spec/Commons/QuantitiesAndUnits/"
	xmlns:cmns-ra="https://www.omg.org/spec/Commons/RegistrationAuthorities/"
	xmlns:cmns-rga="https://www.omg.org/spec/Commons/RegulatoryAgencies/"
	xmlns:cmns-txt="https://www.omg.org/spec/Commons/TextDatatype/"
	xmlns:dct="http://purl.org/dc/terms/"
	xmlns:idmp-chg="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"
	xmlns:idmp-ctcae="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/"
	xmlns:idmp-doco="https://spec.pistoiaalliance.org/idmp/ontology/EXT/DocumentComponents/"
	xmlns:idmp-dtp="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/"
	xmlns:idmp-eura="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"
	xmlns:idmp-eurga="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"
	xmlns:idmp-meddra="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/"
	xmlns:idmp-mprd="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"
	xmlns:idmp-nara="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/"
	xmlns:idmp-narga="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/"
	xmlns:idmp-phprd="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11616-PharmaceuticalProducts/"
	xmlns:idmp-plu="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/"
	xmlns:idmp-ra="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"
	xmlns:idmp-snomed="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/"
	xmlns:idmp-sub="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"
	xmlns:idmp-ucum="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/"
	xmlns:idmp-uom="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/"
	xmlns:lcc-3166-1="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"
	xmlns:lcc-639-1="https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/"
	xmlns:lcc-cr="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"
	xmlns:lcc-lr="https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/"
	xmlns:mvf-trm="https://www.omg.org/spec/MVF/ISO1087-VocabularyForTermsAndDefinitions/"
	xmlns:owl="http://www.w3.org/2002/07/owl#"
	xmlns:po="http://purl.org/spar/po/"
	xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
	xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
	xmlns:skos="http://www.w3.org/2004/02/skos/core#"
	xmlns:snomed="https://lookup.snomedtools.org/"
	xmlns:xsd="http://www.w3.org/2001/XMLSchema#">
	
	<owl:Ontology rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/">
		<rdfs:label>Novartis&apos; PLUVICTO® Example Ontology</rdfs:label>
		<dct:abstract>This ontology provides an example for some of the data related to the substance, amlodipine, to demonstrate substance and basis of strength representation.</dct:abstract>
		<dct:description>Example using Pluvicto focusing on clinical particulars with multiple adverse events referenced from content in the EMA and FDA patient information documents</dct:description>
		<dct:license rdf:datatype="&xsd;anyURI">https://opensource.org/licenses/MIT</dct:license>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/AnnotationVocabulary/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Classifiers/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Collections/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/ContextualDesignators/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Designators/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Documents/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Identifiers/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Organizations/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/PartiesAndSituations/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/ProductsAndServices/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/QuantitiesAndUnits/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/RegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/TextDatatype/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/"/>
		<owl:versionIRI rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/20230701/Examples/PluvictoExample/"/>
		<idmp-chg:hasMaturityLevel rdf:resource="&idmp-chg;Informative"/>
		<cmns-av:copyright>Copyright (c) 2022-2023 EDM Council, Inc.</cmns-av:copyright>
		<cmns-av:copyright>Copyright (c) 2022-2023 Pistoia Alliance, Inc.</cmns-av:copyright>
		<cmns-av:usageNote>This example is for illustration purposes only. The data provided may not be up-to-date, and in some cases, &apos;dummy&apos; data has been included. The product information included here shall not be used for any other purpose than for educational purposes regarding the IDMP-O implementation.</cmns-av:usageNote>
	</owl:Ontology>
	
	<owl:NamedIndividual rdf:about="https://lookup.snomedtools.org/">
		<rdf:type rdf:resource="&idmp-dtp;ControlledVocabulary"/>
		<rdf:type rdf:resource="&cmns-cds;CodeSet"/>
		<rdf:type rdf:resource="&cmns-ra;Registry"/>
		<rdfs:label>SNOMED-CT Concept Lookup</rdfs:label>
		<skos:definition>SNOMED-CT API for accessing concepts registered in SNOMED CT</skos:definition>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetan">
		<rdf:type rdf:resource="&idmp-sub;ChemicalSubstance"/>
		<rdfs:label>lutetium (177Lu) vipivotide tetraxetan</rdfs:label>
		<cmns-dsg:hasName rdf:resource="&idmp-plu;Lutetium177LuVipivotideTeraxetan-CommonName"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetan-CommonName">
		<rdf:type rdf:resource="&idmp-sub;SubstanceName"/>
		<cmns-cls:isClassifiedBy rdf:resource="&idmp-sub;SubstanceNameClassifier-CommonName"/>
		<cmns-txt:hasTextValue>lutetium (177Lu) vipivotide tetraxetan</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetanAsActiveIngredientInPluvicto">
		<rdf:type rdf:resource="&idmp-mprd;ActiveIngredient"/>
		<rdfs:label>lutetium (177Lu) vipivotide tetraxetan as active ingredient in Pluvicto</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-plu;Lutetium177LuVipivotideTeraxetan"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-DecreasedAppetite">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DecreasedAppetite"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-DecreasedAppetite-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusion"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-DecreasedAppetite-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>???</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Hypersensitivity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Hypersensitivity"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Hypersensitivity-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusion"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Hypersensitivity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<dct:reference rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-6.1"/>
		<cmns-txt:hasTextValue>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Myelosuppression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Myelosuppression"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Myelosuppression-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusion"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-Myelosuppression-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia,
						and neutropenia. In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets(9%), decreased
						leukocytes(7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade ≥ 3 pancytopenia
						occurred in 1.1% (which includes two fatal events) in patients treated with PLUVICTO. Two deaths(0.4%) due to
						intracranial hemorrhage and subdural hematoma in association with thrombocytopenia were observed in patients who
						received PLUVICTO. One death due to sepsis and concurrent neutropenia was observed in patients who received
						PLUVICTO.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-RedBloodCellCountLow">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/RedBloodCellCountLow"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-RedBloodCellCountLow-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Pluvicto1000MBqPerMlSolutionForInjectionInfusionUndesirableEffect-RedBloodCellCountLow-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>???</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-plu;PluvictoMarketingAuthorizationByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAContraindication">
		<rdf:type rdf:resource="&idmp-mprd;Contraindication"/>
		<idmp-mprd:hasContraindicationText>
			<owl:NamedIndividual>
				<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndicationText"/>
				<dct:reference rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-6.1"/>
				<cmns-txt:hasTextValue>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</cmns-txt:hasTextValue>
			</owl:NamedIndividual>
		</idmp-mprd:hasContraindicationText>
		<idmp-mprd:isContraindicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMATherapeuticIndicationTreatmentOfPSMACancer">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndication"/>
		<idmp-mprd:hasIndicationAsDiseaseSymptomProcedure rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ProstateCancer"/>
		<idmp-mprd:hasTherapeuticIndicationText>
			<owl:NamedIndividual>
				<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndicationText"/>
				<cmns-txt:hasTextValue>Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy</cmns-txt:hasTextValue>
			</owl:NamedIndividual>
		</idmp-mprd:hasTherapeuticIndicationText>
		<idmp-mprd:isTherapeuticIndicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ASTOrALTElevation">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AlanineAminotransferaseIncreased"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AspartateAminotransferaseIncreased"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ASTOrALTElevation-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ASTOrALTElevation-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>AST or ALT elevation | AST or ALT &gt;5 times ULN in the absence of liver metastases</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia | Grade 2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia | Grade 3</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-DryMouth">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DryMouth"/>
		<idmp-mprd:hasUndesirableEffectText>
			<owl:NamedIndividual>
				<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
				<cmns-txt:hasTextValue>Dry mouth | Grade 3</cmns-txt:hasTextValue>
			</owl:NamedIndividual>
		</idmp-mprd:hasUndesirableEffectText>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ElectrolyteOrMetabolicAbnormalities">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ElectrolyteAbnormality"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/MetabolicDisorder"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ElectrolyteOrMetabolicAbnormalities-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-ElectrolyteOrMetabolicAbnormalities-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Electrolyte or metabolic abnormalities | Grade ≥2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-Fatigue-Grade3">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fatigue"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-Fatigue-Grade3-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-Fatigue-Grade3-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Fatigue | Grade ≥3</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-FractureInWeightBearingBones">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fracture"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-FractureInWeightBearingBones-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-FractureInWeightBearingBones-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Fracture in weight-bearing bones</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-NonHaematologicalToxicity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade4"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade5"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-NonHaematologicalToxicity-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-NonHaematologicalToxicity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Non-haematological toxicity (clinically significant, not otherwise stated) in Grade ≥2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-RenalToxicity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ToxicityRenal"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-RenalToxicity-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-RenalToxicity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Renal toxicity</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-SpinalCordCompression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/SpinalCordCompression"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-SpinalCordCompression-Text"/>
		<idmp-mprd:isUndesirableEffectFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductInEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMAUndesirableEffect-SpinalCordCompression-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Spinal cord compression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-plu;PluvictoMarketingAuthorizationByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDATherapeuticIndication">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndication"/>
		<idmp-mprd:hasIndicationAsDiseaseSymptomProcedure rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT//concept/MalignantTumorOfProstateDisorder"/>
		<idmp-mprd:hasTherapeuticIndicationText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDATherapeuticIndication-Text"/>
		<idmp-mprd:isTherapeuticIndicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInUS"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDATherapeuticIndication-Text">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndicationText"/>
		<cmns-txt:hasTextValue>PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMarketingAuthorizationByEMA">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/idmp-eurga;EuropeanMedicinesAgency"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMarketingAuthorizationByFDA">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/idmp-narga;UnitedStatesFoodAndDrugAdministration"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMedicinalProductInEU">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>PLUVICTO® medicinal product in EU</rdfs:label>
		<cmns-dsg:hasName>
			<idmp-mprd:MedicinalProductName>
				<cmns-txt:hasTextValue>Pluvicto 1,000 MBq/mL solution for injection/infusion</cmns-txt:hasTextValue>
			</idmp-mprd:MedicinalProductName>
		</cmns-dsg:hasName>
		<cmns-pts:playsRole rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMedicinalProductInUS">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>PLUVICTO® medicinal product in US</rdfs:label>
		<cmns-dsg:hasName>
			<idmp-mprd:MedicinalProductName>
				<cmns-txt:hasTextValue>PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use</cmns-txt:hasTextValue>
			</idmp-mprd:MedicinalProductName>
		</cmns-dsg:hasName>
		<cmns-pts:playsRole rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AlanineAminotransferaseIncreased">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Alanine aminotransferase increased</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10001551"/>
		<cmns-txt:hasTextValue>Alanine aminotransferase increased</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Anaemia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10002034"/>
		<cmns-txt:hasTextValue>Anaemia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AspartateAminotransferaseIncreased">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Aspartate aminotransferase increased</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10003481"/>
		<cmns-txt:hasTextValue>Aspartate aminotransferase increased</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DecreasedAppetite">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Decreased appetite</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10061428"/>
		<cmns-txt:hasTextValue>Decreased appetite</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DryMouth">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Dry Mouth</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10013781"/>
		<cmns-txt:hasTextValue>Dry Mouth</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ElectrolyteAbnormality">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Electrolyte abnormality</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10014410"/>
		<cmns-txt:hasTextValue>Electrolyte abnormality</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fatigue">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Fatigue</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10016256"/>
		<cmns-txt:hasTextValue>Fatigue</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fracture">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Fracture</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10017076"/>
		<cmns-txt:hasTextValue>Fracture</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Hypersensitivity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Hypersensitivity</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10020751"/>
		<cmns-txt:hasTextValue>Hypersensitivity</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Leukopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10024384"/>
		<cmns-txt:hasTextValue>Leukopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/MetabolicDisorder">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Metabolic disorder</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10058097"/>
		<cmns-txt:hasTextValue>Metabolic disorder</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Myelosuppression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Myelosuppression</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10028584"/>
		<cmns-txt:hasTextValue>Myelosuppression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Neutropenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10029354"/>
		<cmns-txt:hasTextValue>Neutropenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia">
		<rdf:type rdf:resource="&idmp-eura;MedDRALowestLevelTerm"/>
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdfs:label>Pancytopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10033661"/>
		<cmns-txt:hasTextValue>Pancytopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ProstateCancer">
		<rdf:type rdf:resource="&idmp-mprd;IndicationAsDiseaseSymptomProcedure"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRAPreferredTerm"/>
		<rdfs:label>Prostate cancer</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10060862"/>
		<cmns-txt:hasTextValue>Prostate cancer</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/RedBloodCellCountLow">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Red blood cell count low</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10038156"/>
		<cmns-txt:hasTextValue>Red blood cell count low</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/SpinalCordCompression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Spinal cord compression</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10041549"/>
		<cmns-txt:hasTextValue>Spinal cord compression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Thrombocytopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10043554"/>
		<cmns-txt:hasTextValue>Thrombocytopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ToxicityRenal">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Toxicity renal</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10044258"/>
		<cmns-txt:hasTextValue>Toxicity renal</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10001551">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10001551</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10002034">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10002034</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10003481">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10003481</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10013781">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10013781</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10014410">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10014410</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10016256">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10016256</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10017076">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10017076</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10020751">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10020751</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10024384">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10024384</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10028584">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10028584</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10029354">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10029354</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10033661">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10033661</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10038156">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10038156</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10041549">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10041549</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10043554">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10043554</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10044258">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10044258</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10058097">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10058097</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10060862">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10060862</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10061428">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10061428</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT//concept/MalignantTumorOfProstateDisorder">
		<rdf:type rdf:resource="&idmp-mprd;IndicationAsDiseaseSymptomProcedure"/>
		<rdf:type rdf:resource="&cmns-cxtdsg;ContextualDesignation"/>
		<rdf:type rdf:resource="&mvf-trm;VocabularyEntry"/>
		<owl:sameAs rdf:resource="&snomed;363346000"/>
		<rdfs:label>Malignant tumor of prostate (disorder)</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT//id/399068003"/>
		<cmns-ra:isRegisteredIn rdf:resource="https://lookup.snomedtools.org/"/>
		<cmns-txt:hasTextValue>Malignant tumor of prostate (disorder)</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT//id/399068003">
		<rdf:type rdf:resource="&cmns-ra;RegisteredIdentifier"/>
		<cmns-txt:hasTextValue>399068003</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf">
		<rdf:type rdf:resource="&cmns-doc;Document"/>
		<dct:format rdf:resource="http://www.iana.org/assignments/media-types/application/pdf"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#FullPrescribingInformation"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Document-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#FullPrescribingInformation">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Chapter"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#FullPrescribingInformation-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#FullPrescribingInformation-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/ChapterTitle"/>
		<idmp-doco:hasText>FULL PRESCRIBING INFORMATION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Chapter"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Most common adverse reactions (≥ 20%) are fatigue, dry mouth, nausea,
					anemia, decreased appetite, and constipation. (6.1)
					Most common laboratory abnormalities (≥ 30%) are decreased lymphocytes,
					decreased hemoglobin, decreased leukocytes, decreased platelets, decreased
					calcium, and decreased sodium. (6.1)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-AdverseReactions-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>ADVERSE_REACTIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#HighlightsOfPrescribingInformation-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/ChapterTitle"/>
		<idmp-doco:hasText>HIGHLIGHTS OF PRESCRIBING INFORMATION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1-Title"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-1-Text"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-1-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive
					metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway
					inhibition and taxane-based chemotherapy.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-1-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2 INDICATIONS AND USAGE</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2-Title"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.5"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2 DOSAGE AND ADMINISTRATION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1"/>
		<idmp-doco:hasText>PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see
					Warnings and Precautions (5.1)]. Use waterproof gloves and effective radiation shielding when handling PLUVICTO.
					Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are
					qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience
					and training have been approved by the appropriate governmental agency authorized to license the use of
					radiopharmaceuticals.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.1-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2.1 Important Safety Instructions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Select patients with previously treated mCRPC for treatment with PLUVICTO using LOCAMETZ or another approved
					PSMA-11 imaging agent based on PSMA expression in tumors. Additional selection criteria were used in the VISION
					study [see Clinical Studies (14)].
					Refer to the prescribing information for the PSMA imaging agent.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.2-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2.2 Patient Selection</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The recommended PLUVICTO dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 doses, or until disease progression, or unacceptable toxicity.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.3-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2.3 Recommended Dosage</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4-Title"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recommended dosage modifications of PLUVICTO for adverse reactions are provided in Table 1. Management of
					adverse reactions may require temporary dose interruption (extending the dosing interval from every 6 weeks up to every
					10 weeks), dose reduction or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an
					adverse reaction persists for &gt; 4 weeks, treatment with PLUVICTO must be discontinued. The dose of PLUVICTO may
					be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose. If a patient has further adverse reactions that
					would require an additional dose reduction, treatment with PLUVICTO must be discontinued.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2.4 Dosage Modifications for Adverse Reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.5">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.5-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.5-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>2.5 Preparation and Administration</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-3">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-3-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-3-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>3 DOSAGE FORMS AND STRENGTHS</idmp-doco:hasText>
		<idmp-doco:hasText>4 CONTRAINDICATIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-4">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-3-Title"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-4-Text"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>None.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5-Title"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5 WARNINGS AND PRECAUTIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation
						exposure is associated with an increased risk for cancer.
						Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with
						PLUVICTO consistent with institutional good radiation safety practices, patient treatment procedures, Nuclear Regulatory
						Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home.
						Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation.
						Before the patient is released, the healthcare provider should explain the necessary radioprotection precautions that the
						patient should follow to minimize radiation exposure to others [see Patient Counseling Information (17)]. Following
						administration of PLUVICTO, advise patients to limit close contact (less than 3 feet) with household contacts for 2 days
						or with children and pregnant women for 7 days. Following administration of PLUVICTO, advise patients to refrain from
						sexual activity for 7 days. Following administration of PLUVICTO, advise patients to sleep in a separate bedroom from
						household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.1-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5.1 Risk From Radiation Exposure</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia,
						and neutropenia. In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased
						leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade ≥ 3 pancytopenia
						occurred in 1.1% (which includes two fatal events) in patients treated with PLUVICTO. Two deaths (0.4%) due to
						intracranial hemorrhage and subdural hematoma in association with thrombocytopenia were observed in patients who
						received PLUVICTO. One death due to sepsis and concurrent neutropenia was observed in patients who received
						PLUVICTO.
						Reference ID: 4957021
						Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently
						discontinue PLUVICTO and clinically treat patients based on the severity of myelosuppression [see Dosage and
						Administration (2.4)].</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5.2 Myelosuppression</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:relation rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-2.4"/>
		<idmp-doco:hasText>PLUVICTO can cause severe renal toxicity. In the VISION study, Grade 3 or 4 acute kidney injury (3%) and increased
						creatinine (0.9%) occurred in patients treated with PLUVICTO.
						Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform
						kidney function laboratory tests, including serum creatinine and calculated CLcr, before and during treatment with
						PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on the severity of renal toxicity [see
						Dosage and Administration (2.4)].</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5.3 Renal Toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action,
						PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)]. No animal studies using lutetium Lu 177
						vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development;
						however, all radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm. Advise male patients
						with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for
						14 weeks after the last dose [see Use in Specific Populations (8.1, 8.3)].</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.4-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5.4 Embryo-Fetal Toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO may cause infertility in males. The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a
						radiation absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility
						[see Use in Specific Populations (8.3)].</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.5-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>5.5 Infertility</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.2"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6-Text"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6-Title"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The following clinically significant adverse reactions are described elsewhere in the labeling:
• Myelosuppression [see Warnings and Precautions (5.2)]
• Renal Toxicity [see Warnings and Precautions (5.3)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>6 ADVERSE REACTIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Section"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1-Title">
		<rdf:type rdf:resource="http://purl.org/spar/doco/SectionTitle"/>
		<idmp-doco:hasText>6.1 Clinical Trials Experience</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1">
		<rdf:type rdf:resource="&po;Table"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-1"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-2"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<cmns-col:hasIndex>1</cmns-col:hasIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Adverse reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Severity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Dose Modification</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-10-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade 3 dry mouth after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-11-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Gastrointestinal toxicity
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3 (not amenable to medical intervention)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-12-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 2 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade ≥ 3 gastrointestinal toxicity after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-13-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Fatigue
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-14-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 2 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Electrolyte or metabolic abnormalities
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-15-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>AST or ALT elevation
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>AST or ALT &gt; 5 times ULN in the absence of liver metastases</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-16-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Other non-hematologic toxicity
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any unacceptable toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-17-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any serious adverse reaction that requires treatment delay of &gt; 4 weeks</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-18-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any recurrent Grade 3 or 4 or persistent and intolerable Grade 2 adverse reaction after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-19-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Myelosuppression
(Anemia, thrombocytopenia,leukopenia, or neutropenia)
[see Warnings and Precautions (5.2)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-3-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade ≥ 3 myelosuppression after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-4-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-5.3"/>
		<idmp-doco:hasText>Renal toxicity
[see Warnings and Precautions (5.3)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed serum creatinine	increase (Grade ≥ 2)
• Confirmed CLcr &lt; 30 mL/min;calculate using Cockcroft-Gaultwith actual body weight</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-5-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed ≥ 40% increase from baseline serum creatinine and
• Confirmed &gt; 40% decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weight</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-6-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3 renal toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-7-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent renal toxicity after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-8-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:reference rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Section-6.1"/>
		<idmp-doco:hasText>Dry mouth
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-9-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3">
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-1"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-2"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-3"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-4"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-5"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-3-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-1"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-2"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-2"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Column-3"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-4"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-4"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Col-5">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-1-Row-2-Column-5"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowSpan>
		<idmp-doco:hasText>Adverse Reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableColumnSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnSpan>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO Plus BSoC
(N = 529)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-4-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableColumnSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnSpan>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-1-Column-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>BSoC
(N = 205)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>All Grades
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grades 3 to 4
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-4-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>All Grades
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-5">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-5-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#Table-3-Row-2-Column-5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grades 3 to 4
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf">
		<rdf:type rdf:resource="&cmns-doc;Document"/>
		<dct:format rdf:resource="http://www.iana.org/assignments/media-types/application/pdf"/>
		<dct:title>Pluvicto : EPAR - Product information</dct:title>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Chapter-4"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Chapter-4">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Chapter"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Chapter-4-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Chapter-4-Header">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>CLINICAL PARTICULARS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Document-Header">
		<idmp-doco:hasTextContent>HIGHLIGHTS OF PRESCRIBING INFORMATION\n
					These highlights do not include all the information needed to use
					PLUVICTO safely and effectively. See full prescribing information for
					PLUVICTO.\n
					PLUVICTOTM (lutetium Lu 177 vipivotide tetraxetan) injection, for
					intravenous use\n
					Initial U.S. Approval: 2022</idmp-doco:hasTextContent>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-1-Header">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:containsText>INDICATIONS AND USAGE</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO is a radioligand therapeutic agent indicated for the treatment of
					adult patients with prostate-specific membrane antigen (PSMA)-positive
					metastatic castration-resistant prostate cancer (mCRPC) who have been
					treated with androgen receptor (AR) pathway inhibition and taxane-based
					chemotherapy. (1)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Chapter"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1-Text"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1-Header">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Therapeutic indications</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor
					(AR) pathway inhibition is indicated for the treatment of adult patients with progressive
					prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer
					(mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy (see
					section 5.1).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.2">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Chapter"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.2-Text"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Section-4.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Posology and method of administration</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1">
		<rdf:type rdf:resource="http://purl.org/spar/doco/Table;"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-1"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-2"/>
		<po:contains rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-3"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Header"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-1-Header"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-1-Header">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasText>Adverse reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-2-Header"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-2-Header">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasText>Severity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-3-Header"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Col-3-Header">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasText>Dose modification</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-1-Header">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recommended dose modifications of Pluvicto for adverse reactions</idmp-doco:hasText>
		<idmp-doco:hasText>Table 1: Recommended Dosage Modifications of PLUVICTO for Adverse Reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#Table-3-Header">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Table 3: Adverse Reactions (≥ 5%) in Patients with PSMA-positive mCRPC Who Received PLUVICTO Plus BSoC in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>

</rdf:RDF>